CRIS

Curis Inc. (CRIS) | Rumor.io

Curis

CRIS

Attention (50-day avg)0%

Attention rank (50-day avg)#4,491

Bullish sentiment (50-day avg)0%

Price to earnings ratio0.22

Market capitalization2M

Earnings per share3.65

Dividend yield (TTM)—

Revenue (annual)9.4M

Net income (annual)-7.6M

Social

What share of all stock conversation is about CRIS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jun 30

The company's stock, $CRIS, has been experiencing significant price movements, with some users predicting a potential increase to $500.
There is a possibility of a premarket pop for $CRIS, which could impact its price.
Some users are discussing the company's need to reach a certain price level, specifically above $1.00, to become Nasdaq compliant without having to reverse split.

Generated by AI

Sentiment

Of the messages about CRIS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.6% +3.4
Bearish	—	—	—	21.4% -3.4

Bullish· Jan 15

$CRIS is expected to reach $20 stock soon, with all ratings potentially increasing 10-fold.
The company is undervalued at current levels, with even all 5 analysts agreeing on its potential.
$CRIS is showing signs of bullish accumulation, including higher highs, tight pullbacks, and low volume on red days.

Bearish· Nov 17

$CRIS's halted trading and volatile price swings may be due to its low float and potential for short squeezes.
The company's management may be a concern, with some investors suggesting it is a reflection of the stock's undervaluation.
$CRIS's low price and potential for a short squeeze may make it a attractive target for pharmaceutical companies looking to acquire ownership.

Generated by AI

Topics

Of the messages about CRIS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	34.38%
Announcements	—	—	—	23.3%
Controversies	—	—	—	0%
Earnings	—	—	—	2.27%
Macro	—	—	—	5.68%
Technical Analysis	—	—	—	34.38%

Earnings· Nov 1

CRIS beats earnings estimates by $0.09 and revenue estimates.
CRIS reported a loss of $0.22, beating consensus estimates of a loss of $0.31.
CRIS earnings report is seen as a positive outcome for the company.

Announcements· Aug 30

The FDA has allowed patient enrollment to resume in the monotherapy dose escalation of Emavusertib in the TakeAim Leukemia study.
Curis, Inc. (CRIS) has announced that the FDA has lifted the hold on the monotherapy dose escalation of Emavusertib in the TakeAim Leukemia study.
The US FDA has notified Curis that it may resume enrollment of additional patients in the monotherapy phase of the Emavusertib trial for acute myeloid leukemia and myelodysplastic syndromes.

Technical Analysis· Aug 18

$CRIS is near resistance levels at $1.84, $1.94, and $2.02, and support levels at $1.48, $1.40, and $1.30.
The 10-day Moving Average of $CRIS crossed below its 50-day Moving Average on August 8, 2022.
$CRIS is expected to break above $1.7 with a gap close target of $2.3, and has run +40.8% since being named.

Generated by AI

Community

Of the messages about CRIS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	26.37%
Newcomers	100%	100%	100%	73.63%

Regulars· Nov 17

Truist initiated a BUY on Curis with a price target of $26, calling the stock "extremely undervalued" with significant upside potential due to market cap and the lead drug emavusertib's potential in AML/MDS/CLL markets.
Cantor Fitzgerald analysts boosted earnings estimates for Curis, Inc., and the stock is seeing significant attention as it rises ahead of the 2023 ASH conference, with average trade volume increasing to the low 7 digits.
Curis is being compared to Pharmacyclics, a company that was acquired for $21B in 2015, due to the potential of its lead drug emavusertib, and is being considered "undervalued" by some, but its valuation is also attributed to concerns about management.

Newcomers· Mar 19

The company reported a net loss of $7.6 million for 2025, improving from a net loss of $43.4 million in 2024.
The net loss per share decreased from $6.88 in 2024 to $0.58 in 2025.
Curis' financial performance improved in the fourth quarter of 2025 compared to the same period in 2024.

Generated by AI

News

Analysts Are Bullish on These NA Stocks: Curis (CRIS), Canadian National Railway (CNI)

Detailed price information for Canadian National Railway (CNI-N) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Curis prices $5.6 million public offering at $1.50 per share

1mo agoInvesting.com

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of commo

1mo agoYahoo Finance

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

The fair value price target for Curis has been reset from US$280.00 to US$42.67, which represents a very large downward adjustment in the modeled target level. Analysts link this shift to updated assumptions around emavusertib and the TakeAim chronic lymphocytic leukemia study, where price targets now reflect explicit probabilities of success, peak sales estimates and timing. As you read on, you will see how this evolving narrative around Curis might influence the way you track the stock from...

1mo agoYahoo! Finance Canada

Curis doses first five patients in leukemia drug study

2mo agoInvesting.com

Also Discussed

Investors talking about CRIS also mention

#	Name	Attention
1	ONCT - Oncternal Therapeutics, Inc.	——
2	Celldex Therapeutics IncCLDX	0%+0
3	AFMD - Affimed N.V.	——
4	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
5	ALX Oncology Holdings Inc.ALXO	0%0
6	Palvella Therapeutics IncPIRS	0%0
7	PDS Biotechnology CorporationPDSB	0%-0.01
8	Cardiff Oncology Inc.CRDF	0%+0
9	FOLD - Amicus Therapeutics, Inc.	——
10	Agenus Inc.AGEN	0.01%-0.01

Curis Inc.

Healthcare
Biotechnology

Curis Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for cancer treatment. The company’s current portfolio centers on targeted drug candidates designed to address specific cancer-driving pathways and patient groups, with programs spanning hematologic malignancies and solid tumors. Its work includes small-molecule and antibody-based therapies, as well as marketed or advanced-stage assets in oncology and related disease areas. Curis also collaborates with research and development partners to advance its pipeline and expand the clinical profile of its programs. Based in Lexington, Massachusetts, Curis Inc. plays a specialized role in the oncology drug development market, where it contributes to the discovery and testing of precision medicines intended for use in areas with significant unmet medical need.

Website

Location

Building C

Lexington, MA, 02421

United States

Social

What share of all stock conversation is about CRIS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jun 30

The company's stock, $CRIS, has been experiencing significant price movements, with some users predicting a potential increase to $500.
There is a possibility of a premarket pop for $CRIS, which could impact its price.
Some users are discussing the company's need to reach a certain price level, specifically above $1.00, to become Nasdaq compliant without having to reverse split.

Generated by AI

Sentiment

Of the messages about CRIS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.6% +3.4
Bearish	—	—	—	21.4% -3.4

Bullish· Jan 15

$CRIS is expected to reach $20 stock soon, with all ratings potentially increasing 10-fold.
The company is undervalued at current levels, with even all 5 analysts agreeing on its potential.
$CRIS is showing signs of bullish accumulation, including higher highs, tight pullbacks, and low volume on red days.

Bearish· Nov 17

$CRIS's halted trading and volatile price swings may be due to its low float and potential for short squeezes.
The company's management may be a concern, with some investors suggesting it is a reflection of the stock's undervaluation.
$CRIS's low price and potential for a short squeeze may make it a attractive target for pharmaceutical companies looking to acquire ownership.

Generated by AI

Topics

Of the messages about CRIS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	34.38%
Announcements	—	—	—	23.3%
Controversies	—	—	—	0%
Earnings	—	—	—	2.27%
Macro	—	—	—	5.68%
Technical Analysis	—	—	—	34.38%

Earnings· Nov 1

CRIS beats earnings estimates by $0.09 and revenue estimates.
CRIS reported a loss of $0.22, beating consensus estimates of a loss of $0.31.
CRIS earnings report is seen as a positive outcome for the company.

Announcements· Aug 30

The FDA has allowed patient enrollment to resume in the monotherapy dose escalation of Emavusertib in the TakeAim Leukemia study.
Curis, Inc. (CRIS) has announced that the FDA has lifted the hold on the monotherapy dose escalation of Emavusertib in the TakeAim Leukemia study.
The US FDA has notified Curis that it may resume enrollment of additional patients in the monotherapy phase of the Emavusertib trial for acute myeloid leukemia and myelodysplastic syndromes.

Technical Analysis· Aug 18

$CRIS is near resistance levels at $1.84, $1.94, and $2.02, and support levels at $1.48, $1.40, and $1.30.
The 10-day Moving Average of $CRIS crossed below its 50-day Moving Average on August 8, 2022.
$CRIS is expected to break above $1.7 with a gap close target of $2.3, and has run +40.8% since being named.

Generated by AI

Community

Of the messages about CRIS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	26.37%
Newcomers	100%	100%	100%	73.63%

Regulars· Nov 17

Truist initiated a BUY on Curis with a price target of $26, calling the stock "extremely undervalued" with significant upside potential due to market cap and the lead drug emavusertib's potential in AML/MDS/CLL markets.
Cantor Fitzgerald analysts boosted earnings estimates for Curis, Inc., and the stock is seeing significant attention as it rises ahead of the 2023 ASH conference, with average trade volume increasing to the low 7 digits.
Curis is being compared to Pharmacyclics, a company that was acquired for $21B in 2015, due to the potential of its lead drug emavusertib, and is being considered "undervalued" by some, but its valuation is also attributed to concerns about management.

Newcomers· Mar 19

The company reported a net loss of $7.6 million for 2025, improving from a net loss of $43.4 million in 2024.
The net loss per share decreased from $6.88 in 2024 to $0.58 in 2025.
Curis' financial performance improved in the fourth quarter of 2025 compared to the same period in 2024.

Generated by AI

Curis

Social

Jun 30

Bullish· Jan 15

Bearish· Nov 17

Earnings· Nov 1

Announcements· Aug 30

Technical Analysis· Aug 18

Regulars· Nov 17

Newcomers· Mar 19

Analysts Are Bullish on These NA Stocks: Curis (CRIS), Canadian National Railway (CNI)

Curis: Q2 Earnings Snapshot

Curis prices $5.6 million public offering at $1.50 per share

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

Curis doses first five patients in leukemia drug study

Also Discussed

Curis Inc.

Company Information

Location

Analysts Are Bullish on These NA Stocks: Curis (CRIS), Canadian National Railway (CNI)

Curis: Q2 Earnings Snapshot

Curis prices $5.6 million public offering at $1.50 per share

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

Curis doses first five patients in leukemia drug study

Also Discussed

Social

Jun 30

Bullish· Jan 15

Bearish· Nov 17

Earnings· Nov 1

Announcements· Aug 30

Technical Analysis· Aug 18

Regulars· Nov 17

Newcomers· Mar 19